Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmaceutical research and development.

P L McKercher1

  • 1Upjohn Company, Inc., Kalamazoo, Michigan.

Clinical Therapeutics
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

Pharmaceutical research and development (R&D) is vital for industry viability and economic contributions. Understanding R&D

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmaceuticals in Medicare reform.

Clinical therapeutics·1998
Same author

Catastrophic health insurance: impact on the pharmaceutical industry.

American journal of pharmaceutical education·1989
Same author

Comparison of total, free, and salivary phenytoin concentrations in geriatric patients.

Clinical pharmacy·1986
Same author

The elimination of selected drug products from the Michigan Medicaid formulary: a case study.

Hospital formulary·1984
Same author

Impact of peer performance-evaluation on job satisfaction.

American journal of hospital pharmacy·1983
Same author

Effect of pharmacist counseling on drug information recall.

American journal of hospital pharmacy·1982
Same journal

Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

Clinical therapeutics·2026
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
Same journal

Diversity: A Medical Research Imperative.

Clinical therapeutics·2026
Same journal

LOARGYS (pegzilarginase-nbln).

Clinical therapeutics·2026
See all related articles

Area of Science:

  • Pharmaceutical Sciences
  • Health Economics
  • Public Policy

Background:

  • Major pharmaceutical manufacturers heavily invest in research and development (R&D) for business viability.
  • Global pharmaceutical R&D expenditures reached $24 billion in 1990, with significant personnel employed in the US.
  • The profitability of the pharmaceutical industry is often linked to R&D costs, sometimes overshadowing R&D benefits.

Purpose of the Study:

  • To review key aspects of pharmaceutical research and development (R&D).
  • To highlight the economic contributions and importance of pharmaceutical R&D.
  • To discuss proposed reforms for drug approval processes and their potential impact.

Main Methods:

  • Literature review of pharmaceutical R&D.

Related Experiment Videos

  • Analysis of R&D expenditures and personnel.
  • Examination of proposed policy reforms for drug approval.

    • Main Results:

    • Pharmaceutical R&D significantly contributes to increased life expectancy and a positive trade balance for the US.
    • Proposed reforms, including accelerated approval and international cooperation, aim to preserve R&D capabilities.
    • Misunderstanding the role of R&D may lead to detrimental policies.

    Conclusions:

    • Pharmaceutical R&D is crucial for industry competitiveness and national economic benefits.
    • Policy decisions regarding drug approval and regulation should consider the multifaceted value of R&D.
    • Preserving a robust R&D environment is essential for continued innovation and public health advancements.